Sign In
Buy NTRA
$234.76
+5.96 (+2.60%)
At Close: Jun 23, 2026
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
07:00am, Monday, 17'th Jun 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQ
Final Trades: Amazon, Natera and KKR & Co.
01:48pm, Monday, 10'th Jun 2024
The Investment Committee gives you their top stocks to watch for the second half.
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
08:00am, Monday, 03'rd Jun 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthca
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
08:00am, Thursday, 30'th May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
04:05pm, Thursday, 23'rd May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera's management will present at the 2024 Leerink
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
07:30am, Thursday, 23'rd May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data
Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript
11:28pm, Thursday, 09'th May 2024
Natera, Inc. (NASDAQ:NTRA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Solomon Moshkevic
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
07:31pm, Thursday, 09'th May 2024
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Natera Reports First Quarter 2024 Financial Results
04:05pm, Thursday, 09'th May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Rece
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
08:00am, Friday, 03'rd May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability
Natera to Report its First Quarter 2024 Results on May 9
04:05pm, Wednesday, 01'st May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 20
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
07:00am, Wednesday, 01'st May 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
08:00am, Monday, 22'nd Apr 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publicati
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
08:00am, Thursday, 11'th Apr 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasi
